✦ LIBER ✦

Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial

✍ Scribed by Butts, Charles; Socinski, Mark A; Mitchell, Paul L; Thatcher, Nick; Havel, Libor; Krzakowski, Maciej; Nawrocki, Sergiusz; Ciuleanu, Tudor-Eliade; Bosquée, Lionel; Trigo, José Manuel; Spira, Alexander; Tremblay, Lise; Nyman, Jan; Ramlau, Rodryg; Wickart-Johansson, Gun; Ellis, Peter; Gladkov, Oleg; Pereira, José Rodrigues; Eberhardt, Wilfried Ernst Erich; Helwig, Christoph; Schröder, Andreas; Shepherd, Frances A

Book ID: 121512628
Publisher: The Lancet
Year: 2014
Tongue: English
Weight: 546 KB
Volume: 15
Category: Article
ISSN: 1470-2045
DOI: 10.1016/S1470-2045(13)70510-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Concurrent celecoxib versus placebo in p

Concurrent celecoxib versus placebo in patients with stage II–III non-small cell lung cancer: A randomised phase II trial

✍ Dirk De Ruysscher; Johan Bussink; Patrick Rodrigus; Alfons Kessels; Miranda Dirx 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 52 KB

Icotinib versus gefitinib in previously

Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial

✍ Shi, Yuankai; Zhang, Li; Liu, Xiaoqing; Zhou, Caicun; Zhang, Li; Zhang, Shucai; 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 490 KB

Docetaxel plus nintedanib versus docetax

Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial

✍ Reck, Martin; Kaiser, Rolf; Mellemgaard, Anders; Douillard, Jean-Yves; Orlov, Se 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 382 KB

Maintenance pemetrexed plus best support

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

✍ Tudor Ciuleanu; Thomas Brodowicz; Christoph Zielinski; Joo Hang Kim; Maciej Krza 📂 Article 📅 2009 🏛 The Lancet 🌐 English ⚖ 217 KB

Phase III Trial of Maintenance Gefitinib

Phase III Trial of Maintenance Gefitinib or Placebo After Concurrent Chemoradiotherapy and Docetaxel Consolidation in Inoperable Stage III Non-Small-Cell Lung Cancer: SWOG S0023

✍ Kelly, K.; Chansky, K.; Gaspar, L. E.; Albain, K. S.; Jett, J.; Ung, Y. C.; Lau, 📂 Article 📅 2008 🏛 American Society of Clinical Oncology 🌐 English ⚖ 145 KB

Ramucirumab plus docetaxel versus placeb

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

✍ Garon, Edward B (author);Ciuleanu, Tudor-Eliade (author);Arrieta, Oscar (author) 📂 Article 📅 2014 🏛 Elsevier BV 🌐 English ⚖ 389 KB